Frontiers in Pharmacology (Jun 2021)

A Repurposed Drug Screen Identifies Compounds That Inhibit the Binding of the COVID-19 Spike Protein to ACE2

  • Kaleb B. Tsegay,
  • Christiana M. Adeyemi,
  • Edward P. Gniffke,
  • D. Noah Sather,
  • D. Noah Sather,
  • John K. Walker,
  • John K. Walker,
  • Stephen E. P. Smith,
  • Stephen E. P. Smith,
  • Stephen E. P. Smith

DOI
https://doi.org/10.3389/fphar.2021.685308
Journal volume & issue
Vol. 12

Abstract

Read online

Repurposed drugs that block the interaction between the SARS-CoV-2 spike protein and its receptor ACE2 could offer a rapid route to novel COVID-19 treatments or prophylactics. Here, we screened 2,701 compounds from a commercial library of drugs approved by international regulatory agencies for their ability to inhibit the binding of recombinant, trimeric SARS-CoV-2 spike protein to recombinant human ACE2. We identified 56 compounds that inhibited binding in a concentration-dependent manner, measured the IC50 of binding inhibition, and computationally modeled the docking of the best inhibitors to the Spike-ACE2 binding interface. The best candidates were Thiostrepton, Oxytocin, Nilotinib, and Hydroxycamptothecin with IC50’s in the 4–9 μM range. These results highlight an effective screening approach to identify compounds capable of disrupting the Spike-ACE2 interaction, as well as identify several potential inhibitors of the Spike-ACE2 interaction.

Keywords